Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
Oğuzhan Işılay, Bioinformatics Intern at Mersin Üniversity, shared on LinkedIn:
”I recently read and analyzed an interesting research paper on stabilizing Human Blood Clotting Factor VIII (FVIII) using proteins derived from tardigrades.
FVIII is a critical therapeutic protein used in the treatment of Hemophilia A, but it is highly unstable and requires strict cold-chain storage.
This creates major logistical and economic challenges, especially in low-resource settings.
The study explored whether proteins associated with desiccation tolerance in tardigrades (such as CAHS and SAHS proteins) could protect FVIII during repeated drying and rehydration cycles.
Remarkably, some tardigrade proteins preserved FVIII activity significantly better than commonly used stabilizers like trehalose, even after multiple stress cycles.
What I found particularly interesting is the broader implication: bio-inspired stabilization strategies could reduce cold-chain dependency and improve global access to protein-based therapeutics.
This analysis reinforced how concepts from extremophile biology can be directly translated into real-world biotechnological and medical solutions.
Reference.”
Read the full article here.
Article: Natural and engineered mediators of desiccation tolerance stabilize Human Blood Clotting Factor VIII in a dry state
Authors: Maxwell H. Packebush, Silvia Sanchez-Martinez, Sourav Biswas, Shraddha KC, Kenny H. Nguyen, John F. Ramirez, Vincent Nicholson, Thomas C. Boothby

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026